GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Cyclically Adjusted PS Ratio

Zydus Lifesciences (BOM:532321) Cyclically Adjusted PS Ratio : 6.67 (As of May. 28, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Cyclically Adjusted PS Ratio?

As of today (2024-05-28), Zydus Lifesciences's current share price is ₹1058.55. Zydus Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹158.75. Zydus Lifesciences's Cyclically Adjusted PS Ratio for today is 6.67.

The historical rank and industry rank for Zydus Lifesciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

BOM:532321' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.03   Med: 3.39   Max: 6.78
Current: 6.78

During the past years, Zydus Lifesciences's highest Cyclically Adjusted PS Ratio was 6.78. The lowest was 2.03. And the median was 3.39.

BOM:532321's Cyclically Adjusted PS Ratio is ranked worse than
88.43% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs BOM:532321: 6.78

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zydus Lifesciences's adjusted revenue per share data for the three months ended in Mar. 2024 was ₹53.070. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹158.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zydus Lifesciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Zydus Lifesciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Cyclically Adjusted PS Ratio Chart

Zydus Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.37 3.64 2.64 3.38 6.33

Zydus Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.38 3.85 3.99 4.40 6.33

Competitive Comparison of Zydus Lifesciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Cyclically Adjusted PS Ratio falls into.



Zydus Lifesciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Zydus Lifesciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1058.55/158.75
=6.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zydus Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Zydus Lifesciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=53.07/153.0345*153.0345
=53.070

Current CPI (Mar. 2024) = 153.0345.

Zydus Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 19.732 94.103 32.089
201409 20.154 96.780 31.869
201412 21.130 96.780 33.412
201503 23.425 97.163 36.895
201506 22.169 99.841 33.980
201509 22.139 101.753 33.297
201512 22.179 102.901 32.985
201603 22.968 102.518 34.286
201606 22.331 105.961 32.252
201609 22.980 105.961 33.189
201612 22.547 105.196 32.800
201703 24.035 105.196 34.965
201706 21.316 107.109 30.456
201709 31.496 109.021 44.211
201712 31.861 109.404 44.567
201803 30.911 109.786 43.088
201806 28.277 111.317 38.874
201809 28.938 115.142 38.461
201812 34.959 115.142 46.464
201903 32.422 118.202 41.976
201906 34.203 120.880 43.301
201909 31.776 123.175 39.479
201912 34.504 126.235 41.829
202003 35.362 124.705 43.395
202006 33.411 127.000 40.260
202009 35.177 130.118 41.372
202012 35.084 130.889 41.020
202103 34.259 131.771 39.787
202106 38.064 134.084 43.444
202109 35.781 135.847 40.308
202112 34.489 138.161 38.202
202203 36.552 138.822 40.294
202206 38.298 142.347 41.173
202209 38.860 144.661 41.109
202212 41.070 145.763 43.119
202303 47.949 146.865 49.963
202306 49.928 150.280 50.843
202309 42.070 151.492 42.498
202312 42.909 152.924 42.940
202403 53.070 153.035 53.070

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zydus Lifesciences  (BOM:532321) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Zydus Lifesciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences (BOM:532321) Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines